EUVIMEDEUVIMED entdecken
Crossref

Overall Survival With [ 177 Lu]Lu-PSMA-617 in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Bayesian Reanalysis of the PSMAfore Trial

Swayamjeet Satapathy, Kunal R. Chandekar

JCO Clinical Cancer Informatics · 2026-10 · 10 (4)

DOI: 10.1200/cci-26-00168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2026-10. Verfasst von Swayamjeet Satapathy und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose [ 177 Lu]Lu-PSMA-617 significantly improved radiographic progression-free survival versus androgen receptor pathway inhibitor change in chemotherapy-naïve metastatic castration-resistant prostate cancer in the PSMAfore trial. However, overall survival (OS) analysis was affected by significant crossover. Here, we performed a Bayesian reanalysis of the OS data under clinically relevant estimands. Materials and Methods Published summary statistics from final PSMAfore OS analysis were used. Bayesian inference was performed separately for intention-to-treat (ITT) estimand and crossover-adjusted estimand corresponding to the trial prespecified inverse probability-of-censoring weighting (IPCW) analysis. Normal likelihoods were specified on the log hazard ratio (HR) scale, with variances derived from reported CIs. Posterior distributions were obtained analytically using conjugate normal-normal updating. Skeptical, weakly informative, and enthusiastic priors were primarily evaluated, with sensitivity analyses incorporating pessimistic prior and varying prior strength. Posterior median HRs, 95% credible intervals (CrIs), and posterior probabilities of any OS benefit [ P (HR

Zitieren

APA

Satapathy, S., & Chandekar, K. R. (2026). Overall Survival With [ 177 Lu]Lu-PSMA-617 in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Bayesian Reanalysis of the PSMAfore Trial. JCO Clinical Cancer Informatics, 10(4). https://doi.org/10.1200/cci-26-00168

Vancouver

Satapathy S, Chandekar KR. Overall Survival With [ 177 Lu]Lu-PSMA-617 in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Bayesian Reanalysis of the PSMAfore Trial. JCO Clinical Cancer Informatics. 2026;10(4). doi:10.1200/cci-26-00168

BibTeX
@article{Satapathy2026,
  author = {Satapathy, Swayamjeet and Chandekar, Kunal R.},
  title = {Overall Survival With [ 177 Lu]Lu-PSMA-617 in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Bayesian Reanalysis of the PSMAfore Trial},
  journal = {JCO Clinical Cancer Informatics},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/cci-26-00168}
}
Kostenlos starten →